Journal de science de formulation et de biodisponibilité

Transcriptional Analysis for Synergistic Drug Identification in AML

Abstract

Zamari Niazi

Acute Myeloid Leukemia (AML) is a complex and aggressive form of blood cancer characterized by the rapid growth of abnormal white blood cells in the bone marrow. Despite significant advancements in cancer research and treatment, AML remains a challenging disease to combat. Standard chemotherapy regimens have limited efficacy, and many patients face relapse or resistance to treatment. To address these challenges, researchers are turning to innovative approaches such as transcriptional analysis to identify synergistic drug combinations for more effective AML treatment. Transcriptional analysis, also known as gene expression profiling, offers a comprehensive view of the genetic and molecular landscape of AML cells. By examining the activity of thousands of genes simultaneously, researchers can gain valuable insights into the underlying mechanisms of AML and identify potential therapeutic targets. This article explores the role of transcriptional analysis in AML research and its potential for uncovering synergistic drug combinations that can improve patient outcomes.